Global seroprevalence of SARS-CoV-2 antibodies: A systematic review and meta-analysis
Open accessPublished version of a preprint
The DOI matches its Crossref record; 52 of the 52 references it cites were found in a registry or an index.
Abstract
Background: Many studies report the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) antibodies. We aimed to synthesize seroprevalence data to better estimate the level and distribution of SARS-CoV-2 infection, identify high-risk groups, and inform public health decision making. Methods: In this systematic review and meta-analysis, we searched publication databases, preprint servers, and grey literature sources for seroepidemiological study reports, from January 1, 2020 to December 31, 2020. We included studies that reported a sample size, study date, location, and seroprevalence estimate. We corrected estimates for imperfect test accuracy with Bayesian measurement error models, conducted meta-analysis to identify demographic differences in the prevalence of SARS-CoV-2 antibodies, and meta-regression to identify study-level factors associated with seroprevalence. We compared region-specific seroprevalence data to confirmed cumulative incidence. PROSPERO: CRD42020183634. Results: We identified 968 seroprevalence studies including 9.3 million participants in 74 countries. There were 472 studies (49%) at low or moderate risk of bias. Seroprevalence was low in the general population (median 4.5%, IQR 2.4–8.4%); however, it varied widely in specific populations from low (0.6% perinatal) to high (59% persons in assisted living and long-term care facilities). Median seroprevalence also varied by Global Burden of Disease region, from 0.6% in Southeast Asia, East Asia and Oceania to 19.5% in Sub-Saharan Africa (p<0.001). National studies had lower seroprevalence estimates than regional and local studies (p<0.001). Compared to Caucasian persons, Black persons (prevalence ratio [RR] 3.37, 95% CI 2.64–4.29), Asian persons (RR 2.47, 95% CI 1.96–3.11), Indigenous persons (RR 5.47, 95% CI 1.01–32.6), and multi-racial persons (RR 1.89, 95% CI 1.60–2.24) were more likely to be seropositive. Seroprevalence was higher among people ages 18–64 compared to 65 and over (RR 1.27, 95% CI 1.11–1.45). Health care workers in contact with infected persons had a 2.10 times (95% CI 1.28–3.44) higher risk compared to health care workers without known contact. There was no difference in seroprevalence between sex groups. Seroprevalence estimates from national studies were a median 18.1 times (IQR 5.9–38.7) higher than the corresponding SARS-CoV-2 cumulative incidence, but there was large variation between Global Burden of Disease regions from 6.7 in South Asia to 602.5 in Sub-Saharan Africa. Notable methodological limitations of serosurveys included absent reporting of test information, no statistical correction for demographics or test sensitivity and specificity, use of non-probability sampling and use of non-representative sample frames. Discussion: Most of the population remains susceptible to SARS-CoV-2 infection. Public health measures must be improved to protect disproportionately affected groups, including racial and ethnic minorities, until vaccine-derived herd immunity is achieved. Improvements in serosurvey design and reporting are needed for ongoing monitoring of infection prevalence and the pandemic response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“However, given the known variability in dual human data extraction accuracy (reported rates: 65.8-85.5%) 14-19 , original author-extracted values were not treated as a definitive gold standard”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Prior research has shown wide variability in the accuracy of dual human extraction, with reported rates ranging from 65.8-85.5% 14-19 .”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“For human data extraction, we determined sample size using a McNemar test for sample size approximation. Using an estimated human accuracy of 80% (reported rates: 65.8-85.5%) 14-19 , LLM accuracy of 90%, and 95% confidence, we determined a minimum number of 204 variables per study to be extracted.”
From Automation of Systematic Reviews with Large Language Models (2025) · cites this paper as [14]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: the PRISMA Statement.
(2009) · PubMed Central · Cited by 44,859
Cochrane Handbook for Systematic Reviews of Interventions: Cochrane Book Series
(2008) · doi:10.1002/9780470712184 · Cited by 25,048
How to perform a meta-analysis with R: a practical tutorial
Balduzzi, S., Rücker, G., & Schwarzer, G. (2019) · Evidence Based Mental Health · doi:10.1136/ebmental-2019-300117 · Cited by 5,827 · cited 1×
“All meta-analysis and meta-regression were done using the meta package in R [34].”
MethodCochrane Handbook for Systematic Reviews of Interventions
Higgins, J. P. T., Green, S., & Ben Van Den, A. (2020) · International Coaching Psychology Review · doi:10.53841/bpsicpr.2020.15.2.123 · Cited by 5,670
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020) · JAMA · doi:10.1001/jama.2020.12839 · Cited by 4,609 · cited 1×
“Table 5: Differences in seroprevalence estimates by demographic characteristics within studies Factor Reference Group Comparison Group Number of Studies Risk Ratio (95% CI)a Heterogeneity (I 2) Age Adults (18-64) Youth (0-17) 82 0.”
BackgroundMunn, Z., Moola, S., Lisy, K., Riitano, D., & Tufanaru, C. (2015) · International Journal of Evidence-Based Healthcare · doi:10.1097/xeb.0000000000000054 · Cited by 3,131 · cited 1×
“A modified Joanna Briggs Institute (JBI) Critical Appraisal Checklist for Prevalence Studies was used to assess study risk of bias [17].”
MethodBi, Q., Wu, Y., Mei, S., Ye, C., Zou, X., Zhang, Z., Liu, X., Wei, L., Truelove, S. A., Zhang, T., et al. (2020) · The Lancet Infectious Diseases · doi:10.1016/s1473-3099(20)30287-5 · Cited by 1,958 · cited 1×
“Our review found that health care workers who had close contact with confirmed COVID19 cases had a higher risk of seropositivity, consistent with previous reports [45].”
ResultRobust neutralizing antibodies to SARS-CoV-2 infection persist for months
Wajnberg, A., Amanat, F., Firpo, A., Altman, D. R., Bailey, M. J., Mansour, M., McMahon, M., Meade, P., Mendu, D. R., Muellers, K., et al. (2020) · Science · doi:10.1126/science.abd7728 · Cited by 1,195
Buitrago-Garcia, D., Egli-Gany, D., Counotte, M. J., Hossmann, S., Imeri, H., Ipekci, A. M., Salanti, G., & Low, N. (2020) · PLOS Medicine · doi:10.1371/journal.pmed.1003346 · Cited by 1,000 · cited 1×
“However, these case counts inevitably underestimate the true cumulative incidence of infection [3] because of limited diagnostic test availability [4], barriers to testing accessibility [5], and asymptomatic infections [6].”
Background
Research works printed but not linked: 2
- American Society for Microbiology. Supply Shortages Impacting COVID-19 and Non-COVID Testing [Internet]. 2020 [cited 2021 May 15]. Available from: https://asm.org/Articles/2020/September/Clinical- Microbiology-Supply-Shortage-Collecti-1
- Wolters Kluwer. COVID-19 Tools and Resources for Clinicians: Expert Searches [Internet]. 2020. Avail- able from: https://tools.ovid.com/coronavirus/?utm_source=marketo&utm_medium=email&utm_ campaign=0-v035&utm_term=all%20ovid&mkt_tok=eyJpIjoiWkRRM01qWXlPRFV5TnpKbCIsInQiO iIydVZWOUYyRFJJYlg1ZUR4T29sY0tCMGpWcHBVbnpTQWpLTGZQb0RjbnlidUQ2U3lVekxC WjNrN0U4SkZLOE9sM0lHTUlmdXEzMXJcL0pWQkhhSzdGYU92cXJ1RXZ4T3BMc2tmT1ZFMm h2Z09cL0d1MEh6RnowK2NJMGRUbEZSdGQ0VmpQUmpybkljWEpPVnFDUTdnZnlRUT09In0%3D
Cited by
Bergeri, I., Whelan, M. G., Ware, H., Subissi, L., Nardone, A., Lewis, H. C., Li, Z., Ma, X., Valenciano, M., Cheng, B., et al. (2022) · PLOS Medicine · doi:10.1371/journal.pmed.1004107 · Cited by 310
“Our results add global representation and principled estimation of changes in seroprevalence over time as compared to previous evidence syntheses [9,11,12].”
BackgroundResultSelf-citationLewis, H., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · doi:10.1101/2022.02.14.22270934 · Cited by 177
Self-citationLewis, H. C., Ware, H., Whelan, M., Subissi, L., Li, Z., Ma, X., Nardone, A., Valenciano, M., Cheng, B., Noel, K., et al. (2022) · BMJ Global Health · doi:10.1136/bmjgh-2022-008793 · Cited by 173
Self-citationCarrat, F., de Lamballerie, X., Rahib, D., Blanché, H., Lapidus, N., Artaud, F., Kab, S., Renuy, A., Szabo de Edelenyi, F., Meyer, L., et al. (2021) · International Journal of Epidemiology · doi:10.1093/ije/dyab110 · Cited by 138
“0001 Skin lesion (second questionnaire) 384 (3) 13 (5) 39 (4) 0.”
Antibody Responses in COVID-19: A Review
Chvatal‐Medina, M., Cortina, Y. A. M., Grajales, P. J. P., Velilla, P. A., & Rugeles, M. T. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.633184 · Cited by 162
Ioannidis, J. P. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13554 · Cited by 130
“Europe North America Latin America Asia Africa Oceania 11 (11) 3 (1) 1 (1) 1 (1) 0 (0) 0 (0) 52 (13) 22 (1) 17 (2) 14 (5) 2 (2) 0 (0) 33 (13) 1 (1) 3 (1) 2 (1) 1 (1) 0 (0) 8 (7) 1 (1) 1 (1) 0 (0) 0 (0) 0 (0) 22 (21) 15 (2) 3 (3) 10 (9) 1 (1) 0 (0) 13 (13) 1 (1) 1 (1) 0 (0) 1 (1) 0 (0)”
The end of the COVID‐19 pandemic
Ioannidis, J. P. A. (2022) · European Journal of Clinical Investigation · doi:10.1111/eci.13782 · Cited by 121
COVID-19 vaccine strategies must focus on severe disease and global equity
McIntyre, P. B., Aggarwal, R., Jani, I. V., Jawad, J. S., Kochhar, S., MacDonald, N. E., Madhi, S. A., Mohsni, E., Mulholland, K., Neuzil, K. M., et al. (2021) · The Lancet · doi:10.1016/s0140-6736(21)02835-x · Cited by 91
Hossain, A., Nasrullah, S. M., Tasnim, Z., Hasan, M. K., & Hasan, M. M. (2021) · EClinicalMedicine · doi:10.1016/j.eclinm.2021.100770 · Cited by 81
“In a meta-analysis, SARS-CoV-2 seroprevalence ranged from 0.37% to 22.1% for the general population and found a pooled estimate of 3.38% [19].”
InfluentialUpdate on SARS-CoV-2 seroprevalence: regional and worldwide
Rostami, A., Sepidarkish, M., Fazlzadeh, A., Mokdad, A. H., Sattarnezhad, A., Esfandyari, S., Riahi, S. M., Mollalo, A., Dooki, M. E., Bayani, M., et al. (2021) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2021.09.019 · Cited by 75
“Other limitations (including different and timevarying sensitivities and specificities of serological methods; missing studies published in un-indexed, local journals; a lack of data for two-thirds of countries of the world) may also have an effect and has been discussed elsewhere [5,13,14].”
BackgroundResultInfluentialWarszawski, J., Beaumont, A., Seng, R., de Lamballerie, X. N., Rahib, D., Lydié, N., Slama, R., Durrleman, S., Raynaud, P., Sillard, P., et al. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-021-06973-0 · Cited by 80
SARS-CoV-2 seroprevalence in children worldwide: a systematic review and meta-analysis
Naeimi, R., Sepidarkish, M., Mollalo, A., Parsa, H., Mahjour, S., Safarpour, F., Almukhtar, M., Mechaal, A., Chemaitelly, H. S., Sartip, B., et al. (2022) · EClinicalMedicine · doi:10.1016/j.eclinm.2022.101786 · Cited by 80
“(5) Another primary limitation was high heterogeneity among studies anticipated in meta-analyses of global prevalence estimates 52,77,78 ; however, we performed the multivariable meta-regression analysis to identify sources of heterogeneity and could explain 75.6% of the variability among studies.”
InfluentialDevelopment of Prompt Templates for Large Language Model–Driven Screening in Systematic Reviews
Cao, C., Sang, J., Arora, R., Chen, D., Kloosterman, R., Cecere, M., Gorla, J., Saleh, R., Drennan, I., Teja, B., et al. (2025) · Annals of Internal Medicine · doi:10.7326/annals-24-02189 · Cited by 91
“We created a database ( BenchSR ) of 10 previously published SRs spanning 9 unique clinical domains collected through convenience sampling based on Oxford Centre for Evidence-Based Medicine SR question types ( Appendix Table 1 and Supplementary Methods , available at Annals.org) (17 – 26).”
Self-citationEstimating typhoid incidence from community-based serosurveys: a multicohort study
Aiemjoy, K., Seidman, J. C., Saha, S., Munira, S. J., Sajib, M. S. I., Sium, S. M. A., Sarkar, A., Alam, N., Zahan, F. N., Kabir, M. S., et al. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00114-8 · Cited by 67
Excess deaths associated with the Iranian COVID-19 epidemic: A province-level analysis
Ghafari, M., Kadivar, A., & Katzourakis, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.04.015 · Cited by 62
El impacto de la pandemia de COVID-19 sobre la salud. Informe SESPAS 2022
Torres-Cantero, A. M., León, E. E. Á., Morán‐Sánchez, I., Campillo, I. S. L., Bernal, E., Pereña, M. H., & Martínez-Morata, I. (2022) · Gaceta Sanitaria · doi:10.1016/j.gaceta.2022.02.008 · Cited by 57
“La mediana de incidencia acumulada estimada a partir de 968 estudios de seroprevalencia de 74 países hasta el 31 de diciembre de 2020 fue 18.1 veces superior a la notificada a los sistemas de vigilancia 8 .”
Influentialfor the SAPRIS study group, Carrat, F., Touvier, M., Severi, G., Meyer, L., Jusot, F., Lapidus, N., Rahib, D., Lydié, N., Charles, M.-A. A., et al. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-05864-8 · Cited by 49
“A lower infection rate with increasing age was reported in several population-based serological studies [18] which is consistent with our findings, although the risk of severe illness or deaths exponentially increases with age among those infected [19].”
ResultAyoub, H. H., Mumtaz, G. R., Seedat, S., Makhoul, M., Chemaitelly, H. S., & Abu-Raddad, L. J. (2021) · Global Epidemiology · doi:10.1016/j.gloepi.2021.100068 · Cited by 53
COVID‐19 vaccination in children and university students
Ioannidis, J. P. A. (2021) · European Journal of Clinical Investigation · doi:10.1111/eci.13678 · Cited by 49
Adapting Serosurveys for the SARS-CoV-2 Vaccine Era
Duarte, N., Yanes‐Lane, M., Arora, R. K., Bobrovitz, N., Liu, M., Bego, M. G., Yan, T., Cao, C., Gurry, C., Hankins, C. A., et al. (2021) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofab632 · Cited by 46
“Using convenience samples (eg, residual sera or banked blood) can be a convenient and economical way to estimate seroprevalence, keeping in mind potential sampling biases and the challenges of not having access to diagnostic and vaccination histories ([7]).”
Self-citationNeuhauser, H. K., Rosario, A. S., Butschalowsky, H., Haller, S., Hoebel, J., Michel, J., Nitsche, A., Poethko‐Müller, C., Prütz, F., Schlaud, M., et al. (2022) · Scientific Reports · doi:10.1038/s41598-022-23821-6 · Cited by 50
Basto-Abreu, A. C., Carnalla, M., Torres‐Ibarra, L., Martínez, M. R., Martínez-Barnetche, J., López-Martínez, I., Aparicio‐Antonio, R., Shamah‐Levy, T., Alpuche-Aranda, C. M., Rivera, J. Á., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-28232-9 · Cited by 43
Jahan, N., Brahma, A., Kumar, M. S., Bagepally, B. S., Ponnaiah, M., Bhatnagar, T., & Murhekar, M. V. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.353 · Cited by 38
Automation of Systematic Reviews with Large Language Models
Cao, C., Arora, R., Cento, P., Budak, A., Manta, K., Farahani, E., Cecere, M., Selemon, A., Sang, J., Gong, L. X., et al. (2025) · medRxiv · doi:10.1101/2025.06.13.25329541 · Cited by 33
“Our sample included various datasets: the SeroTracker dataset 32 for reviews of prevalence (calibration set adapted from Perlman-Arrow et al. 12 ), the Reinfection 33 and PA-Outcomes 34 datasets for reviews of intervention benefits, the PA-Testing 35 dataset for reviews of diagnostic test accuracy,…”
Self-citationPerlman‐Arrow, S., Loo, N., Bobrovitz, N., Yan, T., & Arora, R. K. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1636 · Cited by 30
“com).(25,26) Each week, our team screens 800–1000 new abstracts using the systematic review platform Covidence.”
MethodSelf-citationSeroprevalence of SARS-CoV-2 in Bhubaneswar, India: findings from three rounds of community surveys
Kshatri, J. S., Bhattacharya, D., Praharaj, I., Mansingh, A., Parai, D., Kanungo, S., Palo, S. K., Giri, S., Pattnaik, M., Barik, S. R., et al. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821000972 · Cited by 29
“However, a recent preprint of a systematic review and meta-analysis of global trends on SARS-CoV-2 seroprevalence based on 56 studies has suggested a lack of gender-based differences in seroprevalence [14].”
BackgroundSeroprevalence of SARS-CoV-2 Antibodies in Africa: A Systematic Review and Meta-Analysis
Hajissa, K., Islam, M. A., Hassan, S. A., Zaidah, A. R., Ismail, N., & Mohamed, Z. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19127257 · Cited by 31
“This finding is higher than the previous estimates of global seroprevalence [56,57].”
ResultWarszawski, J., Meyer, L., Franck, J.-E., Rahib, D., Lydié, N., Gosselin, A., Counil, É., Kreling, R., Novelli, S., Slama, R., et al. (2022) · PLoS ONE · doi:10.1371/journal.pone.0267725 · Cited by 29
Goldfarb, D. A., Mâsse, L. C., Watts, A. W., Hutchison, S. M., Muttucomaroe, L., Bosman, E. S., Barakauskas, V., Choi, A., Dhillon, N., Irvine, M. A., et al. (2022) · BMJ Open · doi:10.1136/bmjopen-2021-057846 · Cited by 27
Sorg, A., Bergfeld, L., Jank, M., Corman, V. M., Semmler, I., Goertz, A., Beyerlein, A., Verjans, E., Wagner, N., von Bernuth, H., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-30482-6 · Cited by 26
Zejda, J. E., Brożek, G. M., Kowalska, M., Barański, K., Kaleta-Pilarska, A. P., Nowakowski, A., Xia, Y., & Buszman, P. E. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18063188 · Cited by 27
SARS-CoV-2 seroprevalence around the world: an updated systematic review and meta-analysis
Azami, M., Moradi, Y., Moradkhani, A., & Aghaei, A. (2022) · European journal of medical research · doi:10.1186/s40001-022-00710-2 · Cited by 24
“Also, in this research, studies were aggregated by different regions of the World Health Organization, while in similar studies, classification was more based on the income level of countries [27, 28].”
MethodResultAnand, S. S., Arnold, C. R., Bangdiwala, S. I., Bolotin, S., Bowdish, D. M. E., Chanchlani, R., de Souza, R. J., Desai, D., Kandasamy, S., Khan, F. G., et al. (2022) · CMAJ Open · doi:10.9778/cmajo.20220031 · Cited by 25
“16 Items include questions on the sampling frame, sampling method, sample size, coverage, validity and reliability of the condition measured, statistical analysis and response rate (Appendix 3, Supplementary Table 1, available at www.cmajopen.ca/content/10/3/E599/ suppl/DC1).”
Pisanic, N., Antar, A. A. R., Kruczynski, K. L., Rivera, M. G., Dhakal, S., Spicer, K., Randad, P. R., Pekosz, A. S., Klein, S. L., Betenbaugh, M. J., et al. (2022) · Journal of Immunological Methods · doi:10.1016/j.jim.2023.113440 · Cited by 21
“Monitoring SARS-CoV-2 antibody responses (Bobrovitz et al., 2021; Chen et al., 2021) induced by natural infection and/or vaccination is important to estimate seroprevalence and to understand transmission patterns that can be driven by asymptomatic exposure or infection, waning immunity, and gaps in…”
Han, J., Baek, H. J., Noh, E., Yoon, K., Kim, J. A., Ryu, S., Lee, K. O., Park, N. Y., Jung, E., Kim, S.-I., et al. (2023) · Epidemiology and Health · doi:10.4178/epih.e2023075 · Cited by 20
Audu, R., Stafford, K. A., Steinhardt, L. C., Musa, A. Z., Iriemenam, N. C., Ilori, E. A., Blanco, N., Mitchell, A. B., Hamada, Y., Moloney, M., et al. (2022) · PLOS Global Public Health · doi:10.1371/journal.pgph.0000363 · Cited by 23
World Health Organization Seroepidemiology Technical Working Group (2021) · Influenza and Other Respiratory Viruses · doi:10.1111/irv.12870 · Cited by 20
SARS-CoV-2 prevalence and immunity: a hospital-based study from Malawi
Meinus, C., Singer, R., Nandi, B., Jagot, O., Becker‐Ziaja, B., Karo, B., Mvula, B., Jansen, A., Baumann, J., & Schultz, A. (2021) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2021.12.336 · Cited by 19
Jalloh, M. F., Zeebari, Z., Nur, S. A., Prybylski, D., Nur, A. A., Hakim, A. J., Winters, M., Steinhardt, L. C., Gatei, W., Omer, S. B., et al. (2022) · Journal of Global Health · doi:10.7189/jogh.12.05049 · Cited by 19
Bobrovitz, N., Noël, K. C., Li, Z., Cao, C., Deveaux, G., Selemon, A., Clifton, D. A., Yanes‐Lane, M., Yan, T., & Arora, R. K. (2023) · Research Synthesis Methods · doi:10.1002/jrsm.1620 · Cited by 20
“These studies have made important contributions to the pandemic response, but their methods have varied widely.(2,4) Accordingly, robust risk of bias (RoB) assessments have been crucial for synthesizing and utilizing trustworthy seroprevalence data for public health decision-making.”
BackgroundSelf-citationMeintrup, D., D, M. N.-M. M., & Borgmann, S. (2021) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph18126680 · Cited by 18
“9 on national levels [25], pointing towards a high level of undetected infections.”
BackgroundSam, I., Chong, Y. M., Abdullah, A., Fu, J. Y. L., Hasan, M. S., Jamaluddin, F. H., Kamarulzaman, A., Lim, K. K., Nor, M. A. M., Pang, Y. K., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.27441 · Cited by 17
“With the recent first detections of the VOCs B.1.351 and B.1.1.7 in Malaysia, there is a continuing high risk of further waves of COVID‐19.”
BackgroundInfluentialSemenova, Y. M., Kalmatayeva, Z., Oshibayeva, A., Mamyrbekova, S. A., Kudirbekova, A., Nurbakyt, A. N., Baizhaxynova, A., Colet, P. C., Glushkova, N., Ivankov, A., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19042263 · Cited by 17
“Quite often, these programs relied on repetitive population-based surveys conducted at predetermined intervals analyzing samples that have population representativeness [17].”
BackgroundSoumah, A. A., Diallo, M. S. K., Guichet, E., Maman, D., Thaurignac, G., Kéita, A. K., Bouillin, J., Diallo, H., Pelloquin, R., Ayouba, A., et al. (2022) · Open Forum Infectious Diseases · doi:10.1093/ofid/ofac152 · Cited by 17
“7) times higher than the corresponding cumulative incidence of PCR-confirmed SARS-CoV-2 infection [15].”
Paul, G., Strnad, P., Wienand, O., Krause, U., Plecko, T., Effenberger-Klein, A., Giel, K. E., Junne, F., Galante-Gottschalk, A., Ehehalt, S., et al. (2022) · Infection · doi:10.1007/s15010-022-01830-x · Cited by 17
“Until large-scale vaccination, mainly antibodies against the spike protein of SARS-CoV-2 were used in sero-epidemiological studies [3].”
MethodPuteková, S., Martinkova, J., Uríčková, A., Kober, L., Reichertová, S., Plančíková, D., & Majdán, M. (2023) · BMC Nursing · doi:10.1186/s12912-023-01356-z · Cited by 18
Prevalence of SARS‐CoV ‐2 infection among oral health care workers worldwide: A meta‐analysis
Bitencourt, F. V., Lia, É. N., Pauletto, P., Martins, C. C., Stefani, C. M., Massignan, C., & Canto, G. D. L. (2022) · Community Dentistry And Oral Epidemiology · doi:10.1111/cdoe.12827 · Cited by 19
Ngalamika, O., Lidenge, S. J., Mukasine, M. C., Kawimbe, M., Kamanzi, P., Ngowi, J. R., Mwaiselage, J. D., & Tso, F. Y. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.12.009 · Cited by 16
“[2] Bobrovitz N, Arora RK, Cao C, Boucher E, Liu M, Donnici C, et al.”
Indenbaum, V., Lustig, Y., Mendelson, E., Hershkovitz, Y., Glatman‐Freedman, A., Keinan‐Boker, L., & Bassal, R. (2021) · Eurosurveillance · doi:10.2807/1560-7917.es.2021.26.48.2101040 · Cited by 15
Kislaya, I., Gonçalves, P., Gomez, V., Gaio, V., Roquette, R., Barreto, M., Sousa‐Uva, M., Torres, A. R., Santos, J., Matos, R., et al. (2022) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2021.2025421 · Cited by 17
“1%), suggesting a similar risk of infection [18].”
BackgroundMethodCarrat, F., Lapidus, N., Ninove, L., Blanché, H., Rahib, D., Villarroel, P. M. S., Touvier, M., Severi, G., Zins, M., Deleuze, J., et al. (2021) · Infection · doi:10.1007/s15010-021-01731-5 · Cited by 15
“The association of SARS-CoV-2 seropositivity in younger adults has been reported in numerous studies [1].”
BackgroundSARS-CoV-2 seroprevalence and associated risk factors in periurban Zambia: a population-based study
Shanaube, K., Schaap, A., Klinkenberg, E., Floyd, S., Bwalya, J., Cheeba, M. M., de Haas, P., Kosloff, B. R., Rupérez, M., Hayes, R., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.021 · Cited by 16
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection
Bert, N. L., & Samandari, T. (2024) · Cellular and Molecular Immunology · doi:10.1038/s41423-024-01127-z · Cited by 18
“An examination of seroprevalence versus case noti fi cations documented a huge unrecorded spread of the virus in resource-constrained regions from January to December 2020 [23] (Fig.”
Benn, C. S., Salinha, A., Mendes, S., Cabral, C. H. P. D. S., Martins, C. L., Nielsen, S., Fisker, A. B., Schaltz‐Buchholzer, F., Jørgensen, C. S., & Aaby, P. (2021) · Public Health · doi:10.1016/j.puhe.2021.11.013 · Cited by 15
Schröder, D., Müller, F., Heesen, G., Hummers, E., Dopfer-Jablonka, A., Vahldiek, K., Klawonn, F., Steffens, S., Mikuteit, M., Niewolik, J., et al. (2023) · PLoS ONE · doi:10.1371/journal.pone.0286014 · Cited by 12
SARS-CoV-2 antibody seroprevalence in Lebanon: findings from the first nationwide serosurvey
Hoballah, A., Haidari, R. E., Siblany, G., Abdel‐Sater, F., Mansour, S., Hassan, H., & Abbas, L. A. (2022) · BMC Infectious Diseases · doi:10.1186/s12879-022-07031-z · Cited by 14
“Consistent with previous reports [25, 26], we found a significant difference between the officially registered number of COVID-19 cases and the extrapolated cumulative number of cases based on seroprevalence data.”
BackgroundResultDusefante, A., Negro, C., D’Agaro, P., Segat, L., Purpuri, A., Cegolon, L., & Filon, F. L. (2022) · Life · doi:10.3390/life12020263 · Cited by 14
“Interpretation of Findings in Relation to Other Studies Whilst a nasopharyngeal swab (NPS) positivity [1,8] and seropositivity [4,12,18] similar to the present study was already reported elsewhere, some studies [15,16,36] found a higher risk of seropositivity for males or females [19].”
BackgroundResultPaduano, S., Galante, P., Berselli, N., Ugolotti, L., Modenese, A., Poggi, A. D., Malavolti, M., Turchi, S., Marchesi, I., Vivoli, R., et al. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph19137882 · Cited by 17
“3 million in data reported from 1 January to 31 December 2020 [16].”
BackgroundResultCholette, F., Fabia, R., Harris, A., Ellis, H., Cachero, K., Schroeder, L., Mesa, C., Lacap, P. A., Arnold, C. R., Galipeau, Y., et al. (2022) · Heliyon · doi:10.1016/j.heliyon.2022.e10270 · Cited by 14
“While molecular and antigen tests remain the standard for diagnosing active coronavirus disease 2019 (COVID-19) [1,2], the breadth and depth of the pandemic will be better understood with the help of serological testing for the presence of antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-Co…”
Buntinx, E., Brochado, L., Borja-Tabora, C., Yu, C. Y., Alberto, E. R., Montellano, M. E. B., Carlos, J., Toloza, L. B., Hites, M., Siber, G. R., et al. (2023) · Vaccine · doi:10.1016/j.vaccine.2023.02.017 · Cited by 16
Arkell, P., Gusmão, C., Sheridan, S. L., Tanesi, M. Y., Gomes, N., Oakley, T., Wapling, J., Alves, L. R. F., Kopf, S., Sarmento, N., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.03.043 · Cited by 13
SARS-CoV-2 Antibody Prevalence and Population-Based Death Rates, Greater Omdurman, Sudan
Moser, W., Fahal, M. A. H., Abualas, E., Bedri, S. A., Elsir, M. T., Mohamed, M. F. E. R. O., Mahmoud, A. B., Ahmad, A. I. I., Adam, M., Altalib, S., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2805.211951 · Cited by 13
Leclercq, V., den Houte, N. V., Gisle, L., Roukaerts, I. D. M., Barbezange, C., Desombere, I., Duysburgh, E., & der Heyden, J. V. (2022) · Viruses · doi:10.3390/v14050920 · Cited by 13
“Additionally, the knowledge on the prevalence of anti-SARS-CoV-2 antibodies in the population is important to better understand the epidemiological situation and provide, among others, valuable information regarding vaccine-induced and/or natural immunity against SARS-CoV-2 infections [7].”
BackgroundBettaieb, J., Cherif, I., Kharroubi, G., Châabane, S., Yazidi, R., Dellagi, M., Snoussi, M. A., Salem, S., Marzouki, S., Rebai, W. K., et al. (2022) · Diagnostics · doi:10.3390/diagnostics12040971 · Cited by 16
“The seroprevalence to SARS-CoV-2 did not differ significantly according to sex, in line with results of previous studies [22,43,49,50].”
ResultFink, R. V., Fisher, L., Sulaeman, H., Dave, H., Levy, M. E., McCann, L., Germanio, C. D., Notari, E. P., Green, V., Cyrus, S., et al. (2022) · Transfusion · doi:10.1111/trf.16943 · Cited by 13
Arnaldo, P., Mabunda, N. J., Young, P. W., Tran, T. M., Sitoe, N. E., Chelene, I., Nhanombe, A., Ismael, N., Júnior, A., Cubula, B., et al. (2022) · Clinical Infectious Diseases · doi:10.1093/cid/ciac516 · Cited by 16
Konu, Y. R., Condé, S., Gbeasor‐Komlanvi, F. A., Sadio, A. J., Tchankoni, M. K., Anani, J., Bitty-Anderson, A. M., Mirindi, B. R., Diallo, F., MIjiyawa, M., et al. (2022) · BMC Public Health · doi:10.1186/s12889-022-14794-2 · Cited by 13
“In Europe, America and Asia, a number of population-based seroprevalence studies have been conducted from 2020 onwards [4, 5, 8].”
BackgroundEndemic oscillations for SARS-CoV-2 Omicron—A SIRS model analysis
Nill, F. (2023) · Chaos Solitons & Fractals · doi:10.1016/j.chaos.2023.113678 · Cited by 13
Sulaeman, H., Grebe, E., Dave, H., McCann, L., Germanio, C. D., Sanghavi, A., Sclar, V., Bougie, D. W., Chatelain, G., Biggerstaff, B. J., et al. (2023) · Microbiology Spectrum · doi:10.1128/spectrum.03234-22 · Cited by 12
Vaughan, A., Duffell, E. F., Freidl, G., Lemos, D. S., Funk, T., Nardone, A., Valenciano, M., Subissi, L., Bergeri, I., Broberg, E., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-064240 · Cited by 12
“…of great value to COVID-19 pandemic response efforts, providing estimates of the true extent and dynamics of SARS- CoV-2 infection overtime and the lessons identified from COVID-19, in particular the need for standardised global serosurveil-lance systems, will inform future pandemic preparedness.”
BackgroundCampbell, H., & Gustafson, P. (2021) · Epidemiology and Infection · doi:10.1017/s0950268821002405 · Cited by 13
“Weighting studies based on their true precision is obviously the goal in any evidence synthesis and we recognise that this is particularly difficult when so many studies may misrepresent the precision of their estimates [53, 54].”
BackgroundMethodInfluentialSARS-CoV-2 Seroprevalence in Western Romania, March to June 2021
Olariu, T. R., Craciun, A. C., Vlad, D. C., Dumitraşcu, V., Marincu, I., & Lupu, M. A. (2021) · Medicina · doi:10.3390/medicina58010035 · Cited by 11
“Furthermore, the disparity in public health responses, local resources, population behavior [22], mitigation efforts, and the effectiveness of the implementation of prevention/control measures [20] may also explain the differences.”
BackgroundReconsidering the COVID-19 vaccine strategy in West and Central Africa
Msellati, P., Sow, K., Desclaux, A., Cottrell, G., Diallo, M., Hesran, J. L., Harczi, G., Alfa, D. A., Touré, A. F., & Manigart, O. (2022) · The Lancet · doi:10.1016/s0140-6736(22)01896-7 · Cited by 11
Occupation and SARS-CoV-2 seroprevalence studies: a systematic review
Boucher, E. L., Cao, C., D’Mello, S., Duarte, N., Donnici, C., Duarte, N., Bennett, G., Adisesh, A., Arora, R. K., Kodama, D., et al. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-063771 · Cited by 11
Self-citationAtkinson, A., Albert, A., McClymont, E., Andrade, J., Beach, L. A., Bolotin, S., Boucoiran, I., Bullard, J., Charlton, C. L., Crane, J. M. G., et al. (2023) · CMAJ Open · doi:10.9778/cmajo.20220045 · Cited by 11
“16,17”
Progression and Predictors of SARS-CoV-2 Antibody Seroreactivity In US Blood Donors
Vassallo, R. R., Dumont, L. J., Bravo, M. D., Hazegh, K. E., & Kamel, H. T. (2021) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2021.07.003 · Cited by 11
“As noted in a global systematic review and meta-analysis of serosurveillance studies, most are methodologically flawed, without correction for demographics or test performance, and employ non-representative sampling [9] .”
Anti SARS-CoV-2 seroprevalence in Zanzibar in 2021 before the Omicron wave
Salum, S. S., Sheikh, M. A., Hebestreit, A., & Kelm, S. (2022) · IJID Regions · doi:10.1016/j.ijregi.2022.06.007 · Cited by 11
Menezes, A., Razafimahatratra, S. L., Wariri, O., Graham, A. L., & Metcalf, C. J. E. (2025) · Trends in Microbiology · doi:10.1016/j.tim.2024.12.006 · Cited by 11
Increasing test specificity without impairing sensitivity: lessons learned from SARS-CoV-2 serology
Perkmann, T., Köller, T., Perkmann‐Nagele, N., Ozsvár-Kozma, M., Eyre, D. W., Matthews, P. C., Bown, A., Stoesser, N. E., Breyer, M., Breyer‐Kohansal, R., et al. (2022) · Journal of Clinical Pathology · doi:10.1136/jcp-2022-208171 · Cited by 13
Duarte, N., Arora, R. K., Bennett, G., Wang, M., Snyder, M. P., Cooperstock, J. R., & Wagner, C. E. (2022) · PLOS Digital Health · doi:10.1371/journal.pdig.0000100 · Cited by 10
Self-citationDonnici, C., Ilincic, N., Cao, C., Zhang, C., Deveaux, G., Clifton, D. A., Buckeridge, D. L., Bobrovitz, N., & Arora, R. K. (2022) · Epidemics · doi:10.1016/j.epidem.2022.100645 · Cited by 11
“Data sources and searching methods have been previously described (Bobrovitz et al., 2021).”
InfluentialSelf-citationHennessey, K. A., Pezzoli, L., & Mantel, C. F. (2023) · Health Research Policy and Systems · doi:10.1186/s12961-023-00973-z · Cited by 10
Duong, S., Burtniak, J., Gretchen, A., Mai, A., Klassen, P., Wei, Y., Loeppky, C., Shaw, S. Y., Bullard, J., Caeseele, P. G. V., et al. (2023) · BMC Public Health · doi:10.1186/s12889-023-17239-6 · Cited by 12
“This trend has been observed globally as well as regionally in Canadian studies [7, 8, 19, 23].”
BackgroundInfluentialCOVID-19 cluster size and transmission rates in schools from crowdsourced case reports
Tupper, P. F., Pai, S., & Colijn, C. (2022) · eLife · doi:10.7554/elife.76174 · Cited by 10
“We base this value on the meta-analysis (5) which reports”
MethodRepresentation and Hesitancy in Population Health Research: Evidence from a COVID-19 Antibody Study
Dutz, D., Greenstone, M., Hortaçsu, A., Lacouture, S., Mogstad, M., Shaikh, A. M., Torgovitsky, A., & van Dijk, W. (2023) · National Bureau of Economic Research · doi:10.3386/w30880 · Cited by 11
Immunogenicity of COVID-19 vaccines in lung cancer patients
Provencio, M., Estival, A., Franco, F., López-Vivanco, G., Saigí, M., Arasanz, H., Díz, P., Carcereny, E., García, J., Aguado, C., et al. (2023) · Lung Cancer · doi:10.1016/j.lungcan.2023.107323 · Cited by 9
Richard, L., Nisenbaum, R. A., Colwill, K., Mishra, S., Dayam, R. M., Liu, M., Pedersen, C., Gingras, A., & Hwang, S. W. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09013-9 · Cited by 11
“This is why COVID-19 studies have often leveraged serologic assay data to measure antibody levels against SARS-CoV-2 infection [9–11], which is accepted by the US Centers for Disease Control and Prevention (CDC) as “supportive evidence” of infection in its revised laboratory diagnostic criteria…”
BackgroundSelf-citationSevere Acute Respiratory Syndrome Coronavirus 2 Serosurveillance in Blood Donor Populations
Patel, E. U., Bloch, E. M., & Tobian, A. A. R. (2021) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiab517 · Cited by 9
Tancredi, S., Chioléro, A., Wagner, C., Haller, M. L., Chocano-Bedoya, P. O., Ortega, N., Rodondi, N., Kaufmann, L., Lorthe, E., Baysson, H., et al. (2023) · Infection · doi:10.1007/s15010-023-02011-0 · Cited by 10
“So far, many SARS-CoV-2 seroprevalence studies have been conducted, both in the general population and in specific subgroups, to monitor the pandemic and inform on population levels of immunity [6–8].”
BackgroundCOVID-19 SeroHub, an online repository of SARS-CoV-2 seroprevalence studies in the United States
Freedman, N. D., Brown, L. L., Newman, L. M., Jones, J. M., Benoit, T. J., Averhoff, F. M., Bu, X., Bayrak, K., Lu, A., Coffey, B. D., et al. (2022) · Scientific Data · doi:10.1038/s41597-022-01830-4 · Cited by 9
Manzanal, A., Vicente, D. A., Alonso, M. M., Azkue, N., Ercibengoa, M., & Marimón, J. M. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1238502 · Cited by 8
“Assuming that the methods used are appropriate and have been correctly implemented, local studies have the limitation of low representativeness due to the small geographical area studied, but the advantage of being able to document all the cases detected, which is why they generally give higher levels of incidence (20…”
MethodFung, C. Y. J., Scott, M., Lerner‐Ellis, J. P., & Taher, J. (2023) · Critical Reviews in Clinical Laboratory Sciences · doi:10.1080/10408363.2023.2254390 · Cited by 8
Dokubo, E. K., Shang, J. D., N’Dir, A., Ndongmo, C. B., Okpu, G., Fadil, Y. M., Dimite, L. E., Angumua, C., Lyonga, E. J., Mayer, M. M., et al. (2022) · Emerging infectious diseases · doi:10.3201/eid2813.221193 · Cited by 8
“Because of limited diagnostic testing during earlier waves of the COVID-19 pandemic and the large number of persons who had asymptomatic or mildly symptomatic infections, the reported number of cases globally is much lower than the actual prevalence (25).”
BackgroundCOVID and Gender: A Narrative Review of the Asia-Pacific Region
Binns, C. W., Lee, M. K., Duong, D. T. T., Lee, A. H., Pham, N. M., & Zhao, Y. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20010245 · Cited by 9
“A global seroprevalence survey included surveys from three Asian countries that found no gender difference in prevalence [26].”
BackgroundMetzger, C., Leroy, T., Bochnakian, A., Jeulin, H., Gégout‐Petit, A., Legrand, K., Schvoerer, É., & Guillemin, F. (2023) · PLoS ONE · doi:10.1371/journal.pone.0269104 · Cited by 11
Rees, E. M., Waterlow, N. R., Lowe, R., & Kucharski, A. J. (2021) · Wellcome Open Research · doi:10.12688/wellcomeopenres.16701.1 · Cited by 10
Neuhauser, H. K., Buttmann‐Schweiger, N., Ellert, U., Fiebig, J., Hövener, C., Offergeld, R., Prütz, F., Sarganas, G., Schaade, L., Rosario, A. S., et al. (2021) · Publication server of the Robert Koch Institute (Robert Kock Institute) · doi:10.25646/8999 · Cited by 8
Santa-Ramírez, H.-A., Wisniak, A., Pullen, N., Zaballa, M.-E., Pennacchio, F., Lorthe, E., Dumont, R., Baysson, H., Guessous, I., & Stringhini, S. (2022) · Frontiers in Public Health · doi:10.3389/fpubh.2022.874252 · Cited by 9
Ma, X., Li, Z., Whelan, M. G., Kim, D., Cao, C., Yanes‐Lane, M., Yan, T., Jaenisch, T., Chu, M., Clifton, D. A., et al. (2022) · Vaccines · doi:10.3390/vaccines10122000 · Cited by 8
“Detailed methods and results from this review have previously been published [14,15].”
BackgroundMethodSelf-citationThon, V., Piler, P., Pavlík, T., Andrýsková, L., Doležel, K., Kostka, D., Pikhart, H., Bobák, M., & Klánová, J. (2023) · BMJ Open · doi:10.1136/bmjopen-2022-068258 · Cited by 8
Metadata
- Authors
- Bobrovitz, N., Arora, R. K., Cao, C., Boucher, E., Liu, M., Donnici, C., Yanes-Lane, M., Whelan, M., Perlman-Arrow, S., Chen, J., Rahim, H., Ilincic, N., Segal, M., Duarte, N., Van Wyk, J., Yan, T., Atmaja, A., Rocco, S., Joseph, A., Penny, L., Clifton, D. A., Williamson, T., Yansouni, C. P., Evans, T. G., Chevrier, J., Papenburg, J., & Cheng, M. P.
- Affiliations
- University of Calgary (CA)
- University of Oxford (GB)
- McGill University (CA)
- University of Toronto (CA)
- University of Waterloo (CA)
- McGill University Health Centre (CA)
- Corresponding author
- Bobrovitz, Niklas
- ORCID
- Venue
- PLOS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2021-06-23
- Volume
- 16
- Issue
- 6
- Pages
- e0252617
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC8221784
- OpenAlex
- W3173470851
- Cited by
- 246
- References
- 49
- Citations by year
- 2026: 10 · 2025: 13 · 2024: 33 · 2023: 66 · 2022: 81 · 2021: 43
- FWCI
- 6.52
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, cc-by)
- medRxiv (acceptedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Federal Open Science Repository of Canada / Le Dépôt fédéral de science ouverte du Canada (submittedVersion, cc-by)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Public Health Agency of Canada via the COVID-19 Immunity Task Force
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Physical Sciences › Mathematics › Modeling and Simulation › COVID-19 epidemiological studies
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 detection and testing
- Keywords
- SARS-CoV-2, COVID-19 pandemic, seroprevalence, immunoglobulins, seroepidemiology, racial and ethnic disparities, indigenous peoples, long-term care facilities, perinatal infection, cumulative incidence, public health decision-making, infection risk factors, high-risk groups, SARS-CoV-2 variants
- MeSH terms
- COVID-19, COVID-19 Serological Testing, Adolescent, Adult, Aged, Antibodies, Viral, Child, Health Personnel, Humans, Middle Aged, Sensitivity and Specificity, Incidence, Seroepidemiologic Studies, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.